Lantheus Medical Imaging has acquired Meilleur Technologies, a deal that will give it exclusive global rights to Meilleur's NAV-4694 (F-18 flutafuranol) beta-amyloid PET imaging agent for Alzheimer's disease.
The purchase expands Lantheus' Alzheimer’s diagnostic portfolio and complements its F-18-labeled PET imaging agent candidate, MK-6240 (florquinitau), which targets tau tangles in Alzheimer's disease, according to the firm.
Under the terms of the agreement, Lantheus will make an upfront payment as well as potential additional development and commercial milestone payments. It will also make royalty payments for research revenue and commercial sales, it said.
